AEGiS-11IAC: Specific T-cell responses in HIV-1-infected patients immunized with a recombinant HIV-1 gp160 vaccine.

11th International AIDS Conference


Vancouver, British Columbia — July 7-12, 1996

Print this Article


Specific T-cell responses in HIV-1-infected patients immunized with a recombinant HIV-1 gp160 vaccine.

Int Conf AIDS 1996 Jul 7-12; 11:222 (abstract no. Tu.A.273)
Leandersson AC, Bratt G, Fredriksson M, Gilljam G, Hinkula J, Nordlund S, Sandstrom E, Wahren B; Swedish Institute for Infectious Disease Control, Dept. Of Virology, Stockholm, Sweden. Fax: 46-8-7351080.

OBJECTIVE: To study the specific T-cell responses in HIV-1 infected individuals immunized with rgp 160 formulated in AlPO4 as an adjuvant. HIV-1-infected individuals have a very low or absent T-cell response to HIV and other antigens.

METHODS: The phase I/II study includes 40 patients with initial CD4+ T-cell counts above 400x106 cells/L. The patients have been repeatedly immunized with rgp 160 i.m. The patients were randomized for additional treatment with Zidovudine (AZT) or placebo during the first six months. The patients have been monitored for more than 45 months. In vitro T-cell proliferation assays with the specific HIV antigen rgp160, the peptide Lp2 and the recall antigens Tetanus, Influensa and Cytomegalovirus has been performed.

RESULTS: A comparison of the T-cell responses between the group which received both rgp 160 and AZT initially and the group which received only rgp 160 showed improved T-cell responses to HIV antigens and also to other antigens in both groups. gp 160 vaccination only, gave a prolonged specific antigen activation while addition of AZT also improved the CD4 trends. All 40 individuals responded to the rgp 160 in the T-cell proliferation assay.

CONCLUSIONS: Immunization with a rgp 160 vaccine stabilizes the CD4 values and gives a strong specific T-cell response in asymptomatic HIV-carriers. HIV-infected individuals immunized with rgp 160 improved their capacity to respond immunologically to HIV antigens and to several recall antigens.

Keywords: AEGIS, AIDS Vaccines, HIV-1, T-Lymphocytes, HIV Envelope Protein gp160, HIV Antigens, Zidovudine, HIV Infections, Antigens, CD4, HIV, HIV Seropositivity, Immunization, Anti-HIV Agents, Vaccination, VaxSyn HIV-1 (gp160) vaccine, In Vitro, Human, ICA11KWDaegis,aidsvaccines,hiv-1,t-lymphocytes,hivenvelopeproteingp160,hivantigens,zidovudine,hivinfections,antigens,cd4,hiv,hivseropositivity,immunization,anti-hivagents,vaccination,vaxsynhiv-1(gp160)vaccine,invitro,human,ica11

960707
TuA273

Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.